Analysts Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) PT at $10.00

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has received an average rating of “Moderate Buy” from the seven brokerages that are presently covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, four have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $10.00.

Several equities research analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of SAB Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. Zacks Research cut shares of SAB Biotherapeutics from a “hold” rating to a “strong sell” rating in a research note on Thursday, March 12th. Chardan Capital boosted their target price on SAB Biotherapeutics from $12.00 to $14.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. Weiss Ratings restated a “sell (d)” rating on shares of SAB Biotherapeutics in a report on Monday, December 29th. Finally, UBS Group assumed coverage on shares of SAB Biotherapeutics in a research note on Wednesday, January 7th. They set a “buy” rating and a $7.00 target price for the company.

SAB Biotherapeutics Price Performance

NASDAQ:SABS opened at $3.94 on Friday. The firm has a market capitalization of $200.74 million, a price-to-earnings ratio of -1.70 and a beta of 0.59. The company has a debt-to-equity ratio of 0.02, a current ratio of 9.46 and a quick ratio of 9.46. The business has a 50 day simple moving average of $4.03 and a 200-day simple moving average of $3.39. SAB Biotherapeutics has a 1 year low of $1.00 and a 1 year high of $6.60.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Monday, March 9th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.30). Equities analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current year.

Institutional Investors Weigh In On SAB Biotherapeutics

Several hedge funds have recently made changes to their positions in the company. Perceptive Advisors LLC bought a new stake in shares of SAB Biotherapeutics in the fourth quarter valued at about $3,004,000. Millennium Management LLC purchased a new position in shares of SAB Biotherapeutics in the 4th quarter valued at $1,212,000. Balyasny Asset Management L.P. bought a new stake in SAB Biotherapeutics during the fourth quarter valued at about $1,778,000. ADAR1 Capital Management LLC raised its holdings in SAB Biotherapeutics by 75.6% in the fourth quarter. ADAR1 Capital Management LLC now owns 26,344 shares of the company’s stock worth $99,000 after purchasing an additional 11,344 shares in the last quarter. Finally, ExodusPoint Capital Management LP purchased a new position in shares of SAB Biotherapeutics in the 4th quarter worth approximately $322,000. 7.82% of the stock is currently owned by hedge funds and other institutional investors.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company’s proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company’s lead programs are directed primarily at infectious diseases.